Publications by authors named "Thrasyvoulos Tzellos"
Introduction: Currently, limited data are available on long-term use of dupilumab to treat atopic dermatitis (AD) in a multinational real-world setting. The aim of this analysis was to report the interim 1-year data for patients with AD enrolled in the GLOBOSTAD registry, including treatment patterns, dupilumab effectiveness and safety, and healthcare burden.
Methods: GLOBOSTAD is an ongoing, 5-year, multinational, prospective, observational study of adult/adolescent (aged ≥ 12 years at baseline) patients with AD who initiated dupilumab in real-world settings according to their local country-specific prescribing guidelines.
Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials.
J Eur Acad Dermatol Venereol
October 2024
Introduction: The International Hidradenitis Suppurativa Severity Score System (IHS4) is a validated tool that measures inflammatory lesions, including draining tunnels, in hidradenitis suppurativa (HS).
Objective: To evaluate secukinumab efficacy using IHS4 in patients with moderate to severe HS.
Methods: Data from the SUNSHINE and SUNRISE trials, which assessed subcutaneous secukinumab 300 mg every 2 (SECQ2W) and 4 (SECQ4W) weeks in adults with moderate to severe HS, were analyzed.
Atopic dermatitis (AD) is a chronic and fluctuating disease. Optimal management of AD and related comorbidities requires seamless coordination across multiple layers of the healthcare system. The objective of this survey was to explore patients' experiences with current management of AD.
View Article and Find Full Text PDFDiscrepancies in hidradenitis suppurativa lesion characterization by providers and patients.
J Eur Acad Dermatol Venereol
January 2025
Article Synopsis
- - The study examines inconsistencies in how healthcare providers and patients identify and count lesions associated with hidradenitis suppurativa (HS), highlighting potential issues in the existing clinical response measurement tool, HiSCR, and the impact of rater training on trial outcomes.
- - An online survey of 47 members from the HISTORIC collaboration revealed significant variability in lesion classification, with many providers differing on whether lesions should be treated as single or multiple entities based on their morphology.
- - Findings suggest a need for standardized, consensus-driven guidelines for rater training in HS clinical trials to improve consistency in lesion characterization and potentially enhance trial results.
First steps into AI-supported hidradenitis suppurativa severity assessment.
J Eur Acad Dermatol Venereol
March 2024
Background: Melanoma disease patterns vary with patient age.
Aim: To evaluate sentinel lymph node biopsy (SLNB) in managing melanoma at differing patient ages.
Methods: Online prediction tools were applied to compare SLNB positivity (SLNB) and survival risk at patient ages 20-80.
International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab.
J Eur Acad Dermatol Venereol
June 2024
Introduction: Insights into real-world treatment of atopic dermatitis (AD) are relevant to clinical decision making. The aim of this analysis was to characterize patients who receive dupilumab for AD in a real-world setting.
Methods: The GLOBOSTAD registry is an ongoing, longitudinal, prospective, observational study of patients with AD who receive dupilumab according to country-specific prescribing information.
Article Synopsis
- A new parameter called IHS4-55, which indicates a 55% reduction in the severity of Hidradenitis Suppurativa (HS), was validated using data from patients treated with adalimumab and placebo.
- The research aimed to externally validate the IHS4-55 in patients treated with antibiotics, assessing its correlation with the reduction of inflammatory lesions and quality of life metrics.
- Results from a study of 283 patients showed that those achieving IHS4-55 experienced significant reductions in inflammatory nodules and had a greater likelihood of improving quality of life scores, supporting its use as a key outcome measure in clinical trials.
Background: Nearly half of patients with hidradenitis suppurativa (HS) report dissatisfaction with their treatment. However, factors related to treatment satisfaction have not been explored.
Objectives: To measure associations between treatment satisfaction and clinical and treatment-related characteristics among patients with HS.
Hidradenitis suppurativa/acne inversa (HS) is a chronic inflammatory disease of the pilosebaceous unit leading to formation of painful, inflammatory nodules, abscesses and tunnels in apocrine gland-bearing areas of the skin. Pain and drainage are the most important symptoms associated with reduction of quality of life in HS. On the other hand, an overlooked symptom in quality of life studies is itch, despite the fact that several studies have reported its importance.
View Article and Find Full Text PDFQuality of Life in Hidradenitis Suppurativa: An Update.
Int J Environ Res Public Health
June 2021
Article Synopsis
- Knowledge about hidradenitis suppurativa (HS) is growing, highlighting its significant negative impact on patients and their families due to factors like severity, comorbidities, and unemployment.
- The Dermatology Life Quality Index (DLQI) is the most common tool to assess the impact of HS, alongside six other HS-specific quality of life instruments like HIDRAdisk and HSQoL-24, although experience using these is limited.
- Various treatments, particularly surgery and the biologic adalimumab, have shown to improve patients' quality of life, though results on other biologics remain mixed or based on small studies.
Article Synopsis
- Studies show that patients with inflammatory bowel and skin diseases, including hidradenitis suppurativa (HS), have a low incidence of COVID-19 and treatments with biological modifiers may even aid in managing the disease.
- Experts suggest that HS does not significantly increase COVID-19 susceptibility, and the use of biological treatments is unlikely to worsen this risk.
- A consensus statement recommends HS patients to get vaccinated against COVID-19, especially those with metabolic syndrome, while noting that the effectiveness of the vaccine may vary among those on biological treatments like adalimumab.
Article Synopsis
- The FDA's approval of adalimumab in 2015 represented progress in treating hidradenitis suppurativa (HS), but its effectiveness varied greatly in practice.
- Recent discussions at the 10th European Hidradenitis Suppurativa Conference highlighted new therapeutic targets, focusing on biologics like bimekizumab and secukinumab, which have shown promising clinical results.
- Overall, while some new treatments targeting interleukins and neutrophil activity show potential, their clinical efficacy remains modest, indicating a need for improved understanding of HS pathogenesis for better drug development.
Background: Tetracyclines and clindamycin plus rifampicin combination therapy are both considered first-line therapy in current hidradenitis suppurativa guidelines. However, evidence for their efficacy is drawn from small studies, often without validated outcomes.
Objective: To assess the 12-week efficacy of oral tetracyclines and a combination of clindamycin and rifampicin.
The 14 authors of the first review article on hidradenitis suppurativa (HS) pathogenesis published 2008 in EXPERIMENTAL DERMATOLOGY cumulating from the 1st International Hidradenitis Suppurativa Research Symposium held March 30-April 2, 2006 in Dessau, Germany with 33 participants were prophetic when they wrote "Hopefully, this heralds a welcome new tradition: to get to the molecular heart of HS pathogenesis, which can only be achieved by a renaissance of solid basic HS research, as the key to developing more effective HS therapy." (Kurzen et al. What causes hidradenitis suppurativa? Exp Dermatol 2008;17:455).
View Article and Find Full Text PDFThere is a need for unified guidance on the management of ocular manifestations of atopic dermatitis and ocular manifestations associated with dupilumab in the Nordic region (Denmark, Finland, Norway and Sweden). This initiative gathered Nordic dermatologists and ophthalmologists to identify consensus in this area using a modified Delphi process. The initiative was led by a Nordic expert panel who developed a questionnaire that was circulated to a wider group.
View Article and Find Full Text PDF